BURLINGAME, CA –  Halo Labs, a pioneer in life science instrumentation, announced the launch of its new Aura^®+ Subscription Program. This game-changing offering allows researchers to leverage the power of its cutting-edge particle analysis technology without the burden of full up-front capital equipment costs.

Aura+ is an all-in-one drug product quality tool that ensures the safety, stability, and efficacy of protein, cell, and gene therapies. Using Backgrounded Membrane Imaging (BMI) and Fluorescence Membrane Microscopy (FMM) technologies, Aura+ brings particle characterization to earlier stages of therapeutic development with just 5 µl of sample.

And now, with the Aura Subscription Program, early-stage biotech researchers gain easier access to this critical tool that enables them to make informed developmental and formulation decisions at earlier stages of therapeutic development, ensuring breakthrough discoveries without compromising their budget or timeline.

“Our mission is to empower researchers with innovative tools that accelerate scientific breakthroughs,” said Rick Gordon, CEO at Halo Labs. “We understand that small biotech companies often cannot afford capital equipment purchases in the current climate and are forced to outsource or postpone critical work. With the Aura+ Subscription Program, we are responding to our customers’ needs and removing barriers to accessing cutting-edge particle analysis technology that can keep their development programs moving forward.”

The Aura+ subscription program includes an instrument, consumables, service, installation, training, and applications support for a flat monthly fee. This program is initially available in North America and Europe.